BBR Partners LLC Sells 60,000 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)

BBR Partners LLC reduced its stake in Ikena Oncology, Inc. (NASDAQ:IKNA) by 46.2% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 70,000 shares of the company’s stock after selling 60,000 shares during the quarter. BBR Partners LLC owned 0.15% of Ikena Oncology worth $115,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Ikena Oncology by 5.6% in the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock valued at $469,000 after acquiring an additional 14,319 shares during the last quarter. FMR LLC raised its holdings in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after purchasing an additional 18,607 shares during the period. NEA Management Company LLC lifted its stake in Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after purchasing an additional 30,013 shares during the last quarter. BML Capital Management LLC grew its holdings in Ikena Oncology by 23.6% during the third quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock valued at $1,251,000 after purchasing an additional 138,174 shares during the period. Finally, Peapod Lane Capital LLC purchased a new stake in Ikena Oncology in the fourth quarter worth $833,000. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Trading Up 0.7 %

IKNA opened at $1.44 on Friday. Ikena Oncology, Inc. has a 12 month low of $1.22 and a 12 month high of $1.94. The company has a market cap of $69.49 million, a PE ratio of -1.17 and a beta of 0.49. The company has a 50 day moving average of $1.49 and a 200 day moving average of $1.62.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Research analysts forecast that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IKNA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a research report on Monday, November 11th. Wedbush restated a “neutral” rating and issued a $2.00 price objective on shares of Ikena Oncology in a research note on Monday, December 23rd.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.